Truist Boosts Teva (TEVA) Stock Target Amid Pipeline Growth Opportunities

Core Insights - Teva Pharmaceutical Industries Limited (NYSE:TEVA) is recognized as one of billionaire Stanley Druckenmiller's top stock picks, with Truist Securities raising its price target to $38 from $36 while maintaining a Buy rating [1] Financial Performance - Teva's Q4 2025 results included a significant one-time contribution of $500 million from the Duvakitug Phase 3 trial [1] Market Challenges - The enactment of the Inflation Reduction Act and recent inventory loading are expected to complicate comparisons for Teva's Austedo franchise in 2026 [3] - The generics division is projected to face a loss of approximately $300 million in sales from gRevlimid in the first quarter of 2026 [3] Growth Opportunities - Despite existing challenges, Truist believes that Teva's expansion is still in its early stages, with several pipeline drivers anticipated in 2026 [4] - A potential FDA ruling on Olanzapine LAI in the latter half of 2026 could present a "de-risked $3B peak sales opportunity" for Teva's schizophrenia portfolio [4] Company Overview - Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines and biopharmaceutical products across the US, Europe, Israel, and internationally [5]